Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.

Journal of medical virology - 1 Nov 2016

Boglione Lucio, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

The treatment of patients affected by active chronic hepatitis B (CHB) could be performed using a finite-time therapy with pegylated-interferon alpha (PEG-IFN) or indefinite time treatment with nucleos(t)ide analogues (NAs). Current practice guidelines do not provide the combined use of PEG-IFN and NAs, but some studies analyzed various combined approach with NAs and PEG-IFN with encouraging result. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Interferon-alpha

Share to Polyethylene Glycols

Source

Identifiers

PMID: 27017932
DOI: 10.1002/jmv.24534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.PMID 27017932Read ↗

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.Semantic proximity Read ↗

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.Semantic proximity Read ↗

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.Semantic proximity Read ↗

Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.Semantic proximity Read ↗

Chronic hepatitis B therapy: available drugs and treatment guidelines.Semantic proximity Read ↗

Hepatitis B: treatment choice and monitoring for response and resistance.Semantic proximity Read ↗

Treatment of chronic hepatitis B: Evolution over two decadesSemantic proximity Read ↗

Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Semantic proximity Read ↗

Sequential HBV Treatment With Tenofovir Alafenamide for Patients With Chronic Hepatitis B: Week 96 Results From a Real-world, Multicenter Cohort StudySemantic proximity Read ↗

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.